Results 121 to 130 of about 247,999 (295)
Addiction, EarlyView.Abstract Aims To describe differences in the expression of genes encoding cannabinoid receptors (CNR1, CNR2), the associated receptor GRP55 and the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGLL) between individuals with alcohol use disorder (AUD) and controls in key mesocorticolimbic brain regions.
María Salud García‐Gutiérrez +5 more
wiley +1 more source
Pharmacogenetics of analgesic drugs [PDF]
, 2013 • Individual variability in pain perception and differences in the efficacy of analgesic drugs are complex phenomena and are partly genetically predetermined.
Branford, R +4 more
core +1 more source
Allosteric Modulation of a Cannabinoid G Protein-coupled Receptor
Journal of Biological Chemistry, 2013 Background: Cannabinoid-1 (CB1) receptor allosteric modulator ORG27569 increases CP55,940 binding, yet antagonizes G protein signaling. Results: ORG27569 binding sterically blocks movement in CB1 extracellular loops and transmembrane helix 6 (TMH6 ...
Derek M. Shore +8 more
semanticscholar +1 more source
Varenicline for cannabis use disorder: A randomized controlled trial
Addiction, EarlyView.Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark +8 more
wiley +1 more source
Transient Receptor Potential Melastatin 8 Channel (TRPM8) Modulation: Cool Entryway for Treating Pain and Cancer [PDF]
, 2016 TRPM8 ion channels, the primary cold sensors in humans, are activated by innocuous cooling (
Ferrer-Montiel, Antonio +3 more
core +1 more source
Extracellular glutamate is not modulated by cannabinoid receptor activity
Scientific ReportsAbstractCannabinoid receptor activation has been proposed to trigger glutamate release from astrocytes located in cortical layer 2/3. Here, we measure the basal concentration of extracellular glutamate in layer 2/3 of mouse somatosensory cortex and find it to be 20–30 nM.
Chiu, Delia N., Carter, Brett C.
openaire +5 more sources
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, EarlyView.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source
Current and emerging “at-site” pain medications: a review
Journal of Pain Research, 2011 Praveen PN Rao, Tarek MohamedSchool of Pharmacy, Health Sciences Campus, University of Waterloo, Waterloo, ON, CanadaAbstract: The myriad pain pathophysiology has intrigued and challenged humanity for centuries.
Rao PPN, Mohamed T
doaj
Insights into cannabinoid receptor 2 (CB2) anterograde trafficking and pharmacological chaperoning
Cellular and Molecular Life SciencesCannabinoid Receptor 2 (CB2) is a promising therapeutic target for modulating inflammation. Canonical signalling responses to receptor ligands are critically dependent on cell surface receptor expression.
Caitlin R. M. Oyagawa +4 more
doaj +1 more source
Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia? [PDF]
, 2016 Cerebellar ataxias represent a spectrum of disorders which are, however, linked by common symptoms of motor incoordination and are typically associated with deficient in Purkinje cell firing activity and, often, degeneration. Cerebellar ataxias currently
Stephens, G. J.
core +1 more source